You are here

Article Text

Article menu
Download PDFPDF
JournalScan
Cardiovascular highlights from non-cardiology journals
  1. Enrique Zolezzi,
  2. James M McCabe
  1. Division of Cardiology, University of Washington, Seattle, Washington, USA
  1. Correspondence to Dr James M McCabe; jmmccabe{at}cardiology.washington.edu

https://doi.org/10.1136/heartjnl-2017-311882

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Surgical or transcatheter aortic valve replacement in intermediate-risk patients (SURTAVI investigators)

    Transcatheter aortic valve replacement (TAVR) is superior to medical therapy in inoperable patients with severe, symptomatic aortic stenosis (AS), and may be the preferred option in high-risk surgical patients. The comparative efficacy of TAVR and surgical aortic valve replacement (SAVR) in intermediate-risk AS patients has been less well studied. The PARTNER 2 randomised trial showed non-inferiority of balloon expandable TAVR compared to SAVR in intermediate-risk patients at …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.